Skip to content

Total Equity at other companies

Pfizer logo
PfizerPFE
$90.1B-0.3%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$41.62M-80.6%
AbbVie logo
AbbVieABBV
-$6.66B-569%
Immunome logo
ImmunomeIMNM
$588.69M+91.7%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$524M-1.3%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$607.69M+177%

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$1.78B+674%
Enterprise value$1.68B+826%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s total equity?
SELLAS Life Sciences Group, Inc. (SLS) reported total equity of $107.41M in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s total equity changed year-over-year?
SELLAS Life Sciences Group, Inc.'s total equity increased by 286.9% year-over-year, from $27.76M to $107.41M.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s total equity?
Over 5 years (2020 to 2025), SELLAS Life Sciences Group, Inc.'s total equity has grown at a 20.4% compound annual growth rate (CAGR), from $27.96M to $70.87M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.